Sanofi secured amlitelimab as part of its $1.1 billion acquisition of Kymab back in 2021. But the writing was already on the ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million ...

Scancell Holdings and Neuphoria Therapeutics have made their union official via a reverse merger that will result in a Nasdaq listing for Scancell and a resolution for Neuphoria’s shareholders afte | ...

Eli Lilly’s triple-G drug retatrutide has hit the primary endpoints of a pair of phase 3 obesity trials, although the peak ...

Roche may have scrapped work on a T-cell engager (TCE) for lupus, but the company’s head of pharma told Fierce Biotech that ...

Despite its status as the “pharmacy of the world,” India’s deep life sciences roots have traditionally been based in ...

The U.S. House of Representatives passed the FDA Modernization Act 3.0 this week, and lawmakers and animal welfare advocates ...

The U.S. Department of Health and Human Services announced new efforts Wednesday aligned with President Donald Trump’s ...

The FDA has authorized Johnson & Johnson’s Ottava Robotic Surgical System as it looks to compete with Intuitive Surgical and Medtronic. Ottava is now FDA-approved for multiple soft tissue surgeries, ...

"We have long contemplated a U.S. listing and concluded that the company has reached a stage of maturity sufficient to ...

A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to ...